环孢素A联合司坦唑醇治疗慢性再生障碍性贫血的疗效观察

目的探讨环孢茵素（CsA）联合司坦唑醇治疗慢性再生障碍性贫血（CAA）的临床疗效及安全性。方法选取符合标准的患者60例，采用随机数字的方法分为观察组和对照组各30例，观察组应用CsA联合司坦唑醇，对照组仅用司坦唑醇，6个月后比较临床疗效。结果治疗前二组患者外周血中Hb、WBC及PLT水平比较差异无统计学意义（P〉0．05）。治疗6个月后二组患者外周血中Hb、WBC及PLT水平较治疗前均升高（P〈0．05）；观察组患者Hb及WBC水平较对照组上升幅度较大，差异有统计学意义（P〈0．05），而二组患者PLT水平差异无统计学意义（P〉0．05）。观察组患者总有效率为86．67％，明显高于对照组的60．00％，差异有统计学意义（P〈0．05）。观察组患者不良反应发生率40．00％，与对照组不良反应发生率36．67％相似，差异无统计学意义（P〉0．05）。结论CsA联合司坦唑醇治疗CAA临床疗效显著，临床用药相关副作用少，安全可靠。

CLINICAL EFFECTS OF CICLOSPORIN A COMBINED WITH STANOZOLOL IN TREATMENT OF CHRONIC APLASTIC ANEMIA

Objective To investigate the safety and clinical therapeutic effects of ciclosporin A （CsA） combined with stanozolol in treatment of chronic aplastic anemia （CAA）. Methods Sixty patients meeting the criteria were selected and randomly divided into observation group and control group, 30 patients each group. The observation group was treated with CsA combined with stanozolol, while the control group treated with only stanozolol, and the clinical therapeutic effects were compared in 6 months. Results The differences in Hb, WBC and PLT levels in the peripheral blood in the patients of the two groups before the treatments were statistically insignificant （P〉0.05）. In 6 months after the treatments, Hb, WBC and PLT levels in the peripheral blood in the patients of both groups were increased when compared with those before the treatments （P〈0.05） ; and Hb and WBC levels in the patients of the observation group were increased more significantly than those of the control group, and the differences were statistically significant （ P〈0.05）, while the difference in PLT level between the patients of the two groups was statistically insignificant （P〉0.05）. The total effective rate of the observation group was 86.67%, significantly higher than that of the control group （60.00%）, and the difference was statistically significant （P〈0.05）. The adverse reaction incidence of the observation group was 40.00 %, similar with that of the control group （36.67M}, and the difference was statistically insignificant （P〉0.05）. Conclusion CsA combined with stanozolol in treatment of CAA has significant clinical therapeutic effects and a few of side effects that are related with clinical medication, and is safe and reliable.